Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the
investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee
joint. A secondary purpose is to evaluate the safety of taking the drug either once a day or
twice a day for 4 weeks.